• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • CCC
  • Chinese certification authorities published measures to support the containment of the corona virus outbreak

Chinese certification authorities published measures to support the containment of the corona virus outbreak

Sunday, 09 February 2020 / Published in CCC, News

Chinese certification authorities published measures to support the containment of the corona virus outbreak

On 04.02.2020, the authorities SAMR (State Administration for Market Regulation) and CNCA (China National Certification Administration) published in their Notice No 9/2020 general support measures to contain the corona virus outbreak. Chinese certification organizations are bound by these requirements.

The measures include:

  • Processes are to be optimized so that personal contact is reduced as much as possible.
  • Factory inspections by a Chinese certification organization, which must be postponed due to the current situation, must be communicated openly with the affected certificate holders in order to fix an alternative date by mutual agreement. Or other solutions are agreed upon.
  • Applications for factories that have stopped production due to the outbreak and are unable to complete an inspection of their manufacturing plant in order to obtain the desired certification (e.g. CCC – China Compulsory Certification), but are subject to a time limit for this, may not be suspended. The necessary inspection should be completed at the latest 3 months after the official announcement that the state of emergency has been lifted.
Tagged under: Factory Inspection, SAMR

What you can read next

Online system for traceability of quality and safety information for elevators nationwide introduction by the end of 2019
Public Consultation on the Inspection Guidelines for Unknown Leachables in Medical Devices
NMPA Extends UDI Database Pilot Phase and DI Submission

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP